ABBV - CIK 0001551152
AbbVie Inc. (ABBV) reported revenue of $56.33B for fiscal year 2024, up 3.7% from $54.32B in fiscal 2023. The figure comes from the company's audited annual report as filed with the SEC.
| Quarter | Period end | revenue |
|---|---|---|
| Q1 | 2024-03-31 | $12.31B |
| Q2 | 2024-06-30 | $14.46B |
| Q3 | 2024-09-30 | $14.46B |
| Q4 | 2024-12-31 | $15.10B |
Calendar quarters as standardized by SEC XBRL frames; the company's fiscal calendar may offset from calendar quarters.
AbbVie Inc. (ABBV) reported revenue of $56.33B for fiscal year 2024, up 3.7% from $54.32B in fiscal 2023. The figure comes from the company's audited annual report as filed with the SEC.
In the following fiscal year (2025), AbbVie Inc. reported revenue of $61.16B, an increase from the $56.33B reported in fiscal 2024.
See the full ABBV revenue history or the complete income statement.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.